succimer

Clinical studies indicate that succimer is a relatively selective and highly effective drug which lowers blood lead concentrations.

Succimer 2010

Clinical studies8,9,12 indicate that succimer is a relatively selective and highly effective medication that lowers blood lead concentrations.

Succimer 2010

Limited data suggest that succimer is dialyzable but that lead chelates are not.

Succimer 2010

Mild, transient elevations of serum transaminases have been observed in approximately 6-10percent of the patients (adults and children) receiving succimer therapy.

Succimer 2010

In addition to a diagnostic blood level concentration determined prior to therapy initiation, patients should be monitored for rebound in blood lead concentrations after therapy, because, as with all chelating agents, elevated blood lead concentrations and associated symptoms may return rapidly after discontinuation of succimer due to redistribution of lead from bone stores to soft tissues.

Succimer 2010

Rechallenge with succimer may be considered if blood lead levels are high enough to warrant retreatment.

Succimer 2010

If rash occurs, other causes should be considered before ascribing the reaction to succimer.

Succimer 2010

The primary indicators of drug efficacy in the controlled trials of oral succimer were a lowering of blood lead concentrations and an increase in urinary lead excretion.

Succimer 2010

Chemet® (succimer) contains the stable meso isomer of dimercaptosuccinic acid which has also been known as DMSA.

Succimer 2010

Because transient elevations of serum transaminase levels have been observed during the course of succimer therapy, serum transaminases should be monitored prior to the initiation of therapy and at least weekly during therapy, particularly in patients with a history of liver disease.

Succimer 2010